Cildraw Trio Tablet combines Cilnidipine 10mg, Olmesartan 40mg, and Chlorthalidone 12.5mg, a triple-action antihypertensive formulation designed for comprehensive blood pressure management and cardiovascular protection. This combination addresses vascular resistance, fluid retention, and elevated blood pressure, providing balanced therapy for hypertensive patients.
Cilnidipine, a calcium channel blocker, reduces peripheral resistance and improves cardiac output. Olmesartan, an angiotensin receptor blocker, relaxes blood vessels and controls blood pressure. Chlorthalidone, a thiazide-like diuretic, supports fluid balance and reduces vascular strain. Together, they provide potent, well-tolerated therapy for patients requiring multi-mechanism blood pressure control.
This triple-combination tablet is widely prescribed for patients with resistant hypertension, high cardiovascular risk, or associated fluid retention. Its clinical efficacy and tolerability make it a preferred choice among cardiologists and general physicians for long-term blood pressure management.
Adding Cildraw Trio Tablet to your cardiology and antihypertensive portfolio strengthens your product range with a high-demand, clinically effective combination. It opens opportunities for hospital supply, retail pharmacy distribution, institutional tenders, export channels, and third-party manufacturing, ensuring consistent market demand and profitability.